Gilead Sciences (NASDAQ:GILD) turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter.

The difference in earnings was even starker: Adjusted EPS of $2.36 beat analyst expectations by a whopping 31% and quadrupled the year-ago quarter.

Yet shares today were flat.

In the video below, health care analysts Michael Douglass and David Williamson give more detail on Gilead's great quarter.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers